Complaint · Sickle cell crisis

Sickle cell crisis: documentation that holds up

Two failures define sickle cell care in the ED: under-treating real pain because the patient is mislabeled drug-seeking, and missing the complication hiding behind the "usual crisis." The defensible chart shows fast, adequate analgesia and that the can't-miss complications were excluded.

01What's at stake

A vaso-occlusive crisis is a diagnosis of exclusion, and most patients in crisis have normal vital signs — comfortable appearance and normal vitals do not mean the pain isn't real (true addiction is <5%; under-treatment is the documented pitfall). Meanwhile fever is an emergency because of functional asplenia, and acute chest syndrome, stroke, and splenic sequestration kill quickly.

02Can't-miss complications

  • Acute chest syndrome — chest pain/fever/hypoxia/new infiltrate; a leading cause of death. Get a CXR for any chest symptoms.
  • Stroke — markedly elevated risk, especially in children; emergent imaging.
  • Splenic sequestration — rapidly falling hemoglobin, can be fatal in hours.
  • Aplastic crisis — parvovirus B19; reticulocytopenia is the clue.
  • Sepsis / serious bacterial infection — functional asplenia; encapsulated organisms.
  • Osteomyelitis vs bone infarct, priapism, cholecystitis — masquerade as crisis.

03History & exam

  • Disease severity: prior ACS/stroke/sequestration, baseline hemoglobin, home opioid regimen and what works. → tailor analgesia
  • Fever is an emergency — consider meningitis, septic arthritis, osteomyelitis plus usual sources. → sepsis
  • Exam each pain site for infection (erythema, fluctuance); spleen/liver size; scleral icterus vs baseline; SpO₂.
  • Normal vital signs do not track crisis severity — don't use them (or a calm demeanor) to doubt the pain.

Skip the typing

Work the case in the Sickle Cell Pain Crisis Workup — it records timely analgesia, the fever/sepsis workup, oxygenation and CXR, and hemoglobin vs baseline, and assembles an MDM that documents the can't-miss complications were considered.

04Management

  • Analgesia within ~30 minutes of arrival — IV opioids titrated every 15 min to meaningful relief; use the patient's known effective regimen; avoid meperidine. Document the timing and reassessments.
  • Fluids: maintenance D5½NS for most; avoid normal-saline boluses unless overtly hypovolemic (overhydration → atelectasis/ACS; large NS → hyperchloremic acidosis promotes sickling).
  • Oxygen only if SpO₂ <92%; incentive spirometry for admitted patients (prevents ACS).
  • Transfuse for the complication, not the number — never transfuse merely because hemoglobin is low (hyperviscosity → pain/ACS/stroke); exchange transfusion for ACS/stroke; immediate transfusion for sequestration.
  • Fever → empiric antibiotics covering encapsulated organisms; CXR; cultures. Never prescribe iron.

05What to document

▼ weak
"Sickle cell, frequent visitor, says 10/10 pain but on phone, vitals normal. Given Toradol, discharged."
▲ defensible
"Known HbSS, typical pain distribution; normal vitals (which do not track crisis severity). VOC reached as a diagnosis of exclusion — no chest symptoms or hypoxia (ACS), non-focal neuro exam (stroke), spleen not enlarged with Hgb at baseline (sequestration), afebrile (sepsis). IV hydromorphone at 1410 (≈22 min from arrival), titrated q15 min to relief; maintenance D5½NS, no NS bolus. Hematology notified. Discharged with follow-up; addiction concerns deferred to hematology, not used to limit ED analgesia."

06Where charts fail

  • Using normal vitals or a calm appearance to doubt the pain, or anchoring on "drug-seeking."
  • Calling it a simple crisis without excluding ACS, stroke, sequestration, and infection.
  • Transfusing for a low hemoglobin number rather than a complication.
  • Giving normal-saline boluses, or treating fever without urgent antibiotics.
  • Not documenting time-to-analgesia and reassessment.

07Sources

  • Glassberg J. Evidence-based management of sickle cell disease in the emergency department. Emergency Medicine Practice (EB Medicine). 2011;13(8).
  • Platt OS, Brambilla DJ, Rosse WF, et al. Mortality in sickle cell disease: life expectancy and risk factors for early death. N Engl J Med. 1994;330:1639-1644.
  • Platt OS, Thorington BD, Brambilla DJ, et al. Pain in sickle cell disease: rates and risk factors. N Engl J Med. 1991;325:11-16.
  • Smith WR, Penberthy LT, Bovbjerg VE, et al. Daily assessment of pain in adults with sickle cell disease. Ann Intern Med. 2008;148:94-101.

© 2026 Kim Trinh, MD. All rights reserved. Educational only — synthesized from EB Medicine and primary literature. Synthetic examples. Not medical advice — apply local protocol and judgment.